PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

News

A critical appraisal of PCSK9 inhibitors: PCSK9 monoclonal antibodies versus small interfering RNA Evolocumab prevents carotid artery wall thickening in paediatric HeFH PCSK9 plays critical role in abdominal aortic aneurysm Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders

Plasma

Is PCSK9 a marker of early vascular disease?

This study suggests that measurement of PCSK9 could be used as a predictor of early vascular disease in the primary prevention setting. Previous reports have suggested the potential of PCSK9 as a possible biomarker of risk for clinical ischaemic events. This study investigated this in…

Posted on 11 July 2017 | Posted in News

Plasma PCSK9 levels higher in PAD

Atherosclerotic peripheral artery disease (PAD) affects more than 200 million people worldwide (1), and is associated with substantial morbidity. More than 50% of people with PAD have concomitant coronary heart disease, cerebrovascular disease, or both (2). Management of more severe disease is costly; in the…

Posted on 13 July 2016 | Posted in News

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation